Acupuncture for Impaired Glucose Tolerance in People With Obesity: A Protocol for a Multicenter Randomized Controlled Trial

Yan Yan¹, Yuanjie Sun¹, Xinlu Wang¹, Lili Zhu¹, Yu Chen² and Zhishun Liu¹*

¹ Department of Acupuncture, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China,
² New Zealand College of Chinese Medicine, Auckland, New Zealand

Background: Impaired glucose tolerance (IGT) is associated with being overweight/obesity and is a powerful risk factor for the disease of diabetes. In addition to lifestyle intervention that shows limited clinical application, acupuncture treatment has been a feasible treatment method for IGT in clinical practice. However, the effectiveness of acupuncture treatment has not been proved in evidence-based practice. Therefore, we design a multicenter randomized controlled trial to evaluate the efficacy and safety of acupuncture treatment for IGT in people with overweight/obesity.

Methods: The trial will be conducted at hospitals in three different sites in China. A total of 196 participants will be recruited and randomly assigned at a ratio of 1:1 to either to the acupuncture group or the sham acupuncture (SA) group. Both groups will receive 30 sessions of treatment for 12 consecutive weeks and will be provided with lifestyle intervention and a 24-week follow-up. The primary outcome will be change in the baseline value of 2-h blood glucose (2hPG) on the 12th week. Additionally, the expectancy of acupuncture, blinding, and safety will also be assessed. All statistical analyses will be performed by two-sided test, and a \( p \)-value of less than 0.05 will be considered statically significant.

Discussion: This study aims to provide quantitative clinical evidence of acupuncture effectiveness and safety in treating IGT in people who are overweight/obese.

Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT05347030].

Keywords: overweight, obesity, impaired glucose tolerance, randomized controlled trial, acupuncture, protocol

INTRODUCTION

Impaired glucose tolerance (IGT), measured by oral glucose tolerance test (OGTT), is an intermediate stage of hyperglycemia between normoglycemia and diabetes (1, 2). The latest research shows that 541 million adults, or 10.6% of adults worldwide, are suffering from IGT (3), with China as the top epicenter. Owing to the similar pathophysiological mechanism of insulin resistance (4–6), IGT is more commonly seen in people who are overweight/obese. The prevalence of IGT in people who are overweight/obese in China reached 46.6% in 2008 (7). If no intervention is administered,
every year, about 7% of individuals with IGT will develop diabetes (8), which is deeply associated with many chronic and acute diseases (3, 9, 10). Meanwhile, vascular complications associated with type 2 diabetes mellitus (T2DM) could occur in the IGT stage, indicating increased risks of cardiovascular and cerebrovascular diseases, microvascular diseases, tumors, and dementia in the future (11–15). Additionally, both pre-diabetes (including IGT) and obesity, like diabetes, have been determined as risk factors for critical coronavirus disease 2019 (COVID-19) (16–18). These diseases tend to cause a great damage to organs, warrant long-term interventions, and require large costs, posing a great challenge to public health across the globe (19).

Fortunately, the hyperglycemia in IGT is reversible (20), which means it is possible to prevent or delay the development of diabetes. At present, the recognized effective interventions include lifestyle modifications and pharmaceuticals.

Lifestyle modifications, including a healthy diet and more physical activity, are first-line treatments for patients with IGT who are overweight/obese (21–24). Research studies in different geographical areas globally have shown that lifestyle modifications reduce the risk of diabetes by more than 50% (8, 25, 26). However, it is difficult to apply the method concluded from lifestyle trials into clinical practice considering the high cost, considerable resources required, and lack of participant adherence to the intervention (27, 28). According to the Finnish Diabetes Prevention Study Group’s study, only 47% of the intervention group had a dietary fat intake of less than 30%, only 36% increased exercise intensity, and only 43% reached the weight loss target (26). Besides, patients with other diseases such as ischemic heart disease are excluded from this benefit, because their physical condition prevents them from achieving the recommended intensity of physical activity.

Several pharmaceuticals have been applied in treating IGT. Metformin was the first medicine shown to be effective (25), and it is also the only drug recommended by the American Diabetes Association for IGT treatment. However, Metformin is less effective than lifestyle modifications (31% vs. 58%), has adverse effects such as gastrointestinal reactions, and is not advised for all subgroups (25). The United States Food and Drug Administration has not approved it for preventive interventions (21). Acarbose is the only available medicine in China for treating IGT. Studies have shown that the risk of patients with IGT developing diabetes within 3.3 years is reduced by 25% (29), but many patients cannot tolerate its gastrointestinal side effects, and the drug is relatively expensive (30). As no sufficient evidence has shown that medication carries long-term efficacy and health economic benefits, relevant guidelines do not widely recommend medication intervention as the major measure to treat IGT.

Therefore, it is urgent to find a treatment method that not only treats IGT in people who are overweight/obese but is also characterized by the advantages of high safety, high compliance, good tolerance, and cost-efficiency.

As an important Traditional, Complementary, and Integrative Medicine (TCIM) therapy, acupuncture treatment has been more and more adopted in clinical practice all over the world. Its efficacy and safety have been preliminarily demonstrated in the treatment of insulin resistance (IR)-related diseases such as obesity, diabetes and its related complications, polycystic ovary syndrome, and hypertension (31–36). Although the physiological and pathological mechanisms of IGT are also related to IR (37, 38), the potential role of acupuncture in the treatment of obese people with IGT has not yet been determined by a well-designed randomized controlled trial (RCT). Therefore, this study is conducted to evaluate the efficacy and safety of acupuncture versus sham acupuncture (SA) on improving glucose metabolism among IGT people with Overweight/Obesity.

METHODS AND ANALYSIS

Study Design

This is a prospective, multicenter, parallel-group, participant- and assessor-blinded randomized trial comprising a comparison between acupuncture and SA treatment for IGT in obese or overweight participants. All procedures and time frames are displayed in Figure 1 as per the guideline CONSORT.

Participants

A total of 196 participants with IGT who are overweight/obese will be recruited from three different hospitals, Guang’anmen Hospital, Shenzhen Luohu District Traditional Chinese Medicine Hospital, and Yan Tai Hospital of Traditional Chinese Medicine, through public advertisements like posters, hospital websites, WeChat public accounts, and the Internet from October 2022 to December 2024. The research staff will introduce the background and process of the study in detail to potential subjects who contact the research team and express interest to participate. Once the informed consent form is signed, participants will be evaluated for eligibility by medical history inquiries, physical examinations, and necessary chemical examinations. The duration of the study for each participant will be 37 weeks, including 1-week baseline period, a 12-week treatment period, and a 24-week follow-up period.

Diagnosis Criteria

The trial will adopt the diagnostic criteria of the World Health Organization [WHO (39)] for IGT (40) and the diagnostic criteria for overweight/obesity in the guidelines for the Prevention and Control of overweight and Obesity in Chinese Adults formulated by the Ministry of Health of China in 2003 (41, 42):

1. IGT: fasting blood glucose (PG) is lower than 7 mmol/L, and 2-h blood glucose (2hPG) after oral 75 g glucose tolerance test (OGTT) is between 7.8 and ∼11.1 mmol/L.
2. overweight: 24 < BMI ≤ 27.9, obesity: BMI ≥ 28, or BMI ≤ 24 but waist circumference ≥ 85 cm (men)/≥ 80 cm (women).

Note: The above two criteria should be met at the same time.

Inclusion Criteria

Participants who meet all of the following criteria might be eligible: (1) those who meet the diagnostic criteria for
overweight/obesity and IGT; (2) 18–60 years old; (3) those who can appropriately describe their wishes, voluntarily fill in the informed consent form, and agree to participate in clinical trials.

Note: The above three criteria should be met at the same time.

**Exclusion Criteria**

Participants will be excluded if they meet any of the following criteria: (1) obesity secondary to heredity, drugs, and diseases; (2) those who have received weight-loss treatment or antidiabetic treatment including acupuncture, drugs, herbal medicine, and nutrient supplements in the past 3 months; (3) those who have taken drugs that have known effects on body weight or appetite in the past 3 months, such as corticosteroids, antidepressants, non-selective antihistamines *in vivo*, and nicotine substitutes; (4) IGT caused by abnormal thyroid function, endocrine tumors, or extensive liver damage; (5) abnormal glucose tolerance caused by thiazide diuretics, β-blockers, nicotinic acid drugs, quinolones, calcineurin inhibitors, interferon-alpha, etc.; (6) participants with serious primary diseases such as heart, lung, brain, liver, or hematopoietic system diseases, progressive malignant tumor, or other serious consumptive diseases; (7) participants with cognitive impairment and severe mental illness; (8) participants with blood coagulation dysfunction and who are scare of needles; (9) pregnant, breastfeeding, or planning to conceive within 37 weeks.

Note: Participants who meet any of the above criteria should be excluded.

**Randomization and Allocation Concealment**

A random number will be generated with the SPSS software and concealed in opaque random envelopes. The envelopes will be prepared by a third party in advance, with the sequence number labeled on the surface and the random number and group allocation information sealed in. The random envelopes...
will be preserved by special personnel who are not involved in treatment and evaluation.

**Blinding**
The participants will be blinded to the group allocation in this study, while the acupuncturists will not be blinded. The outcome will be evaluated by independent assessors who will be blinded to the allocation to minimize the bias associated with data collection. The statisticians will also be blinded to the allocation.

**Intervention**

**Study group:** acupuncture + lifestyle recommendation; control group: sham acupuncture + lifestyle recommendation.

During the 12-week treatment, participants in both the acupuncture and SA groups will receive 30-session treatment, three times per week (once every other day) in the first six weeks and twice per week (with an interval of 2–3 days) in the last six weeks. Certified acupuncturists with no less than one year of clinical experience will perform the treatment. Acupuncture needles (Huatuo, Suzhou Medical Appliance) with the size of 0.3 mm × 40–75 mm will be used in the acupuncture group, while, acupuncture needles (Huatuo, Suzhou Medical Appliance) with the size of 0.2 mm × 25–40 mm will be used in the SA group. The participants in different groups will be treated separately to avoid contamination during the process.

**Acupuncture Group**

The acupuncture point regimen is based on evidence-based clinical practice guidelines of traditional Chinese medicine (43, 44). All acupoints selected and their locations are displayed in Figures 2, 3. For acupoints EX-B3 (Yishu), BL18 (Gansu), BL20 (Pishu), and BL21 (Weishu), needles will be inserted at a depth of 15–25 mm depending on the participants’ somatotype and at an angle of 20° obliquely downward. The needles will be gently rotated and lifted three times to achieve a sense of sourness, distention, and heaviness (de qi), and will be withdrawn afterward immediately.

For GV20 (Baihui), the needle will be inserted backward under the cap membrane at an angle of 45° with the scalp; for GV29 (Yintang), the needle will be inserted downward at an angle of 15° under the periosteum; making the participant feel heavy pressure and acid distension. For acupoints LI11 (Quchi), CV12 (Zhongwan), CV10 (Xiawan), ST25 (Tianshu), CV6 (Qihai), CV4 (Guanyuan), ST40 (Fenglong), and SP6 (Sanyinjiao), needles will be inserted at a depth of 25–35 mm vertically. The needles will be gently rotated and lifted three times to achieve a sense of sourness, distention, and heaviness (de qi), and will be withdrawn afterward immediately.

For sham EX-B3, BL18, BL20, and BL21, needles will be vertically inserted at a depth of 1–2 mm without any manipulation to avoid de-qi sensation and will be withdrawn immediately afterward.

For sham GV20, GV29, LI11, CV12, CV10, ST25, CV6, CV4, ST40, and SP6, needles will be vertically inserted at a depth of 1–2 mm without any manipulation to avoid the de-qi sensation. The needles will be retained for 30 min during each treatment session.

**Lifestyle Recommendation**

Lifestyle recommendations will be made based on expert consensus and previous large-scale studies (45, 46). After randomization, participants in both the acupuncture and the SA groups will receive a brochure with lifestyle recommendations and a 20–30-min face-to-face communication with related specialists on the importance of a healthy lifestyle for the management of IGT and obesity. Specifically, the participants will be encouraged to lose 5~10% of their initial weight via an integrated strategy of diet and exercise. They will be encouraged to limit calorie intake, reducing at least 400–500 kCal daily, to increase their activity gradually according to their individual situation, with the goal of over 30-min medium- or high-intensity physical activities such as brisk walking. Medium- or high-intensity physical activities are defined as reaching 50-70% of the maximum heart rate, being a little strenuous, and having fast breathing but no shortness of breath during exercise. The participants will be encouraged to avoid excessive alcohol intake and quit smoking. Whether these recommendations have been accepted and conducted will be evaluated during each visit.

**Rescue Medication**
The participants will not be encouraged to receive any other treatment or medication for IGT or obesity/overweight during the study period to avoid any influence on the results. If participants receive any other treatment, they will also be included in this study, but all details will be recorded in the case report form.

If diabetes is diagnosed during the study period and regular hypoglycemic drugs are recommended by the specialists, the participants will be allowed to use hypoglycemic drugs for rescue. The details (name, dosage, frequency, start time, and duration of use) of drugs will be documented. The proportion of participants using rescue drugs in the groups will be compared.

**Outcome Measures**

**The Primary Outcome**
The primary outcome will be change in the baseline value of 2hPG at the end of the 12-week treatment; 2hPG is the value of intravenous plasma glucose measured by 75 g OGTT, which is usually conducted to diagnose IGT and observe glucose metabolism (40). When the value of 2hPG fluctuates between 7.8 and 11.1 mmol/L, it will be regarded as IGT, and between 4.4 and 7.7 is the ideal control (40).

**Secondary Outcomes**

(1) Change from baseline value of 2-h blood glucose on weeks 24 and 36.
FIGURE 2 | Stimulation points of the acupuncture group and the sham acupuncture group (back view).
FIGURE 3 | Stimulation points of the acupuncture group and the sham acupuncture group (front view).
Compliance Assessment

Compliance on acupuncture will be estimated by counting how many times the subjects have received the treatment, and the criterion for good compliance will be 80% and above. The calculation formula is as follows: compliance = (the number of times the subject has received treatment/the total number of times the subject should receive the treatment) × 100%.

Safety Assessment

Adverse events (AEs) will be reported by the participants themselves and evaluated by outcome assessors and recorded in detail on AE forms throughout the study period. Based on their potential association with the intervention, AEs will be categorized by acupuncturists and related specialists as treatment-related or non-treatment-related within 24 h of occurrence. Treatment-related AEs include but not limited to broken needles, hematoma, infection, abscess around the location of the needle insertion, fainting, vomiting, nausea, palpitations, dizziness, anorexia, and insomnia that presented during or after acupuncture. Non-treatment-related

Expectation Assessment

Participants' expectations of acupuncture will be evaluated with reference to previous high-quality acupuncture clinical trials (51, 52). The participants will be assessed at baseline by the following two questions: "Do you think acupuncture will be effective in treating the illness?" and "Do you think acupuncture will be effective in controlling weight and decreasing glucose?" The response options will be “Ineffective,” “the effect is not good,” “uncertain,” “has some effect,” or “very effective.”

Blinding Assessment

Blinding will be assessed using the James and Bang blinding indices (53). The participants will be told that they are 50% likely to be allocated to the traditional acupuncture group with deeper needling or to the modern acupuncture group with shallower needling. After the last treatment on week 12, each participant will be assessed with a questionnaire asking, "do you receive traditional acupuncture?," with choice options of Yes or No.
TABLE 1 | Study schedule.

| Period            | Run-in period | Treatment period | Follow-up period |
|-------------------|---------------|------------------|-----------------|
| Day               | 7-0 days      | 4 weeks          | 16 weeks        |
|                   |               | 8 weeks          | 24 weeks        |
|                   |               | 12 weeks         | 36 weeks        |
| Informed consent  | √             |                  |                 |
| Inclusion/exclusion criteria | √             |                  |                 |
| Demography characteristics | √             |                  |                 |
| Medical history   | √             |                  |                 |
| Anthropometry     | √             | √                | √               |
| Islet function    | √             | √                |                 |
| Blood lipid       | √             | √                |                 |
| Blood pressure    | √             | √                |                 |
| SNAQ              | √             | √                | √               |
| IWQOL-Lite        | √             | √                | √               |
| Expectation assessment | √              |                  |                 |
| Blindness assessment |             |                  |                 |
| Combined use of drugs | √             | √                | √               |
| Adverse events    | √             | √                |                 |
| Compliance assessment of acupuncture | √             | √                |                 |
| Compliance assessment of Lifestyle recommendation | √             | √                |                 |

IWQOL-Lite, Impact of Weight on Quality of Life-Lite Questionnaire; SNAQ, Simplified Nutritional Appetite Questionnaire.

AEs refer to any other unexpected AE that happened after the initiation of the study. According to the evaluation criteria of the NHS Committee (56), AEs will be divided into three levels (severe, moderate, and mild). Standardized procedures for AE management, especially for serious AEs, will be prepared, and all researchers and doctors involved will be trained.

Quality Control
Before the trial, all staff will undergo special training on the purpose and content of the trial, treatment strategies, and quality requirements. Monitors will check the participant adverse event table, the participants’ lifestyle recommendation diary card, case report form, etc. once every week as well as the acupuncture operation during the treatment period. Dropouts and withdrawals and the underlying reasons will be documented in detail throughout the trial.

Sample Size Calculation
In this study, change in 2hPG from baseline will be used as the basis for primary sample size estimation, based on the unpublished preliminary data collected from 10 participants in the acupuncture group and 10 SA group controls (-1.16 ± 0.42 mmol/L VS0.97 ± 0.34 mmol/L), and a sample size of 196 participants (98 per group) will need to provide the trial with 80% power with a two-sided significance level of 0.05 and 10% dropouts. The PASS 15 software was used for sample size calculation.

Statistical Analysis
We will use the SPSS V.25 software (IBM Corp., Armonk, NY, United States) to perform all statistical analyses following the intention-to-treat principle. CI will be established at 95% and significance level at 0.05. Missing data will be calculated using the actual observational value without imputation if the dropout rate is no more than 5%. For continuous data, the data will be presented as mean ± SD if normally distributed or as median (IQR) if not normally distributed. Longitudinal continuous data will be compared between the groups by repeated-measures analysis of variance (ANOVA) including group and time-group interaction. Other continuous data will be analyzed by Student's t-test and Wilcoxon rank-sum test, and categorical data by X² test or Fisher's exact test, as appropriate. Linear correlation analysis will be conducted to measure the closeness of linear correlation between variables. Sensitivity analysis will be performed if necessary. A p-value < 0.05 will be considered statistically significant.

DISCUSSION
The disease of diabetes is a global killer and ranks among the top causes of premature death, with 1 in 10 adults living with it and almost half undiagnosed, and obesity is an independent risk factor. People with diabetes are more vulnerable to the COVID-19 and might develop more comorbidities if they are infected (3, 16–18). There is an apparent need to detect diabetes early and preferably to initiate an action during the IGT stage to reverse blood glucose to normal level through appropriate intervention. The principle of preventing the disease before onset is highly valued in the theories of traditional Chinese medicine (57). Stimulating specific points (acupoints) by acupuncture can induce the special sensation of “de qi” (such as soreness, numbness, heaviness, and distension) to regulate the circulation of qi through meridians, thus regulating viscera function and metabolism of glucose and lipid. Previous
animal experiments have shown that the acupoints CV4 and SP6 can activate SIRT1/PGC-1α in skeletal muscle (37) and regulate the expression of key insulin signaling-related molecules, thus relieving insulin resistance in obese diabetic mice (58). Stimulating the acupoints CV12 and ST40 may influence SIRT1 in the hypothalamic arcuate nucleus, inducing an anorectic effect and reducing obesity with IR (59). Additionally, ST25 could also regulate the activity of glucose-inhibited neurons in the lateral hypothalamic area and improve the secretory function of adipose tissue to regulate glucose and lipid metabolism (60). This is the first randomized, multicenter and parallel trial to evaluate the efficacy and safety of acupuncture in improving glucose metabolism among IGT participants who are overweight or obese. It may provide valuable clinical evidence for the treatment of IGT and the prevention of diabetes.

However, some limitations of our study should be acknowledged. First, because of the characteristics of acupuncture, the acupuncturist will not be blinded in our trial, which may cause a potential bias. Second, the use of sham acupoints and minimal acupuncture without any manipulation may cause some biological effects leading to false-negative results. The settings of SA need considerations on how to avoid physiological effects as much as possible while blinding the participants. Acupuncture is a penetrating operation, and acupuncture marks will be left on participants’ body after the needle is withdrawn. Since most of the acupoints in this scheme are in the abdomen and limbs, it is convenient for participants to see whether any acupuncture marks are left after acupuncture. Therefore, to ensure blindness of the participants, we use sham acupoint and micro-acupuncture as a placebo control. However, it is difficult to avoid the non-placebo effect of sham needles, as a slight stimulus or a stronger stimulus of gentle touch may lead to different degrees of neurological responses.

REFERENCES

1. World Health Organization, IDF. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia : Report of a WHO/IDF Consultation. (2006). Available online at: https://www.who.int/publications/i/item/definition-and-diagnosis-of-diabetes-mellitus-and-intermediate-hyperglycaemia (accessed June 21, 2022).

2. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. (2021) 44(Suppl. 1):S15–33. doi: 10.2337/dc21-S002

3. IDF Diabetes Atlas. International Diabetes Federation. (2022). Available online at: https://diabetesatlas.org/ (accessed June 21, 2022).

4. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. (2006) 444:840–6. doi: 10.1038/nature05482

5. Attallah H, Friedlander AL, Hoffman AR. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy. Growth Horm IGF Res. (2006) 16(Suppl. A):S62–7. doi: 10.1016/j.ghir.2006.03.004

6. Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. (1992) 41(5 Suppl. 1):16–9. doi: 10.1016/0026-0495(92)90088-R

7. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. (2010) 362:1090–101. doi: 10.1056/NEJMoa0908292

8. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. (2008) 371:1783–9. doi: 10.1016/s0140-6736(08)60786-7

9. O’Leary K. Diabetes risk after COVID-19. Nat Med. (2020). doi: 10.1038/441591-022-00047-7 [Epub ahead of print].

10. Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-onset diabetes in covid-19. N Engl J Med. (2020) 383:789–90. doi: 10.1056/NEJMc2018688

11. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. (2016) 355:i5953.

12. Lamparter J, Raum P, Pfeiffer N, Peto T, Höhn R, Eiffein H, et al. Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg health study. J Diabetes Complicat. (2014) 28:482–7. doi: 10.1016/j.jdiacomp.2014.02.008

13. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, et al. Diabetes, prediabetes and cancer mortality. Diabetologia. (2010) 53:1867–76. doi: 10.1007/s00125-010-1796-7

14. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, et al. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology. (2011) 77:1126–34. doi: 10.1212/WNL.0b013e31822fb435

15. Chen S, Zhang Q, Dai G, Hu J, Zhu C, Su L, et al. Association of depression with pre-diabetes, undiagnosed diabetes, and previously diagnosed diabetes:

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Institutional Review Board of Guang’ammen Hospital. The participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

ZL conceived the study, initiated the design, and revised the manuscript. YY participated in the design and drafted the manuscript. YS revised the important parts of this manuscript critically. XW and LZ participated in the revision of the manuscript. YC corrected the language problems in the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This study was funded by Guang’anmen Hospital, China Academy of Chinese Medical Sciences (Grant No. 82109).

ACKNOWLEDGMENTS

We thanks all the participants in the study, including the participants, statisticians, acupuncturists, and evaluators, as well as Guang’anmen Hospital for their support. Deep appreciation to Mingdi Li and Liang Chen of the Endocrinology Department of Guang’anmen Hospital for their professional guidance on study design. Thanks to Huan Chen for her suggestion on manuscript revision, and Jinyang Dan for helping with the figure.
a meta-analysis. Endocrine. (2016) 53:35–46. doi: 10.1007/s12020-016-0869-9

16. Vargas-Vázquez A, Bello-Chavolla OY, Ortiz-Brizuela E, Campos-Muñoz A, Mehta R, Villanueva-Reza M, et al. Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Res Care. (2021) 9:e000226. doi: 10.1136/bmjdrc-2020-000226

17. Sosibo AM, Khathi A. Pre-diabetes and COVID-19, could we be missing the silent killer? Exp Biol Med. (2021) 246:369–70. doi: 10.1177/1535370220973451

18. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. (2020) 395:1544–5. doi: 10.1016/s0140-6736(20)31024-2

19. Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: the epidemiological evidence. Annu Rev Public Health. (2021) 42:59–77. doi: 10.1146/annurev-publhealth-090419-102644

20. Söderberg S, Zimmet P, Tuomilehto J, de Courten M, Dowse GK, Chitson P, et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med. (2004) 254:37–47. doi: 10.1111/j.1365-2969.2004.01336.x

21. US Preventive Services Task Force. Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Tuomilehto J, Schwarz P, Lindström J. Long-term benefits from lifestyle interventions for type 2 diabetes. Lancet. (2005) 365:251–64. doi: 10.1016/s0140-6736(05)66278-7

22. Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. (2020) 395:1544–5. doi: 10.1016/s0140-6736(20)31024-2

23. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Tuomilehto J, Schwarz P, Lindström J. Long-term benefits from lifestyle interventions for type 2 diabetes. Lancet. (2005) 365:251–64. doi: 10.1016/s0140-6736(05)66278-7

24. Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: the epidemiological evidence. Annu Rev Public Health. (2021) 42:59–77. doi: 10.1146/annurev-publhealth-090419-102644

25. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. (2002) 346:393–403. doi: 10.1056/NEJMoa012512

26. Tuomilehto J, Lindström J, Eriksson J, Valle T, Härmäläinen H, Ilanne-Parikka I, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. (2001) 344:1343–50. doi: 10.1056/nejmao20010530441801

27. WHO. Global Report on Diabetes. (2016). Available online at: https://www.who.int/publications/i/item/9789241565257 (accessed June 21, 2022).

28. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. (1998) 15:539–53. doi: 10.1034/j.1464-5491.1998.00526.x

29. China Association of Acupuncture-Moxibustion. Evidence-Based Guidelines of Clinical Practice with Acupuncture and Moxibustion: Simple Obesity. Beijing: China Press of Traditional Chinese Medicine (2015).

30. Fang CH, Tong XL, Duan JG, Ni Q, Wei JP, Xie CG, et al. Guide to evidence-based clinical practice of traditional Chinese medicine in pre-diabetes mellitus. J Tradit Chin Med. (2017) 585:5.

31. Chinese Society of Endocrinology, Chinese Diabetes Society, Chinese Endocrinologist Association, Endocrine and Metabolic Disease Branch of Chinese Research Hospital Association, Diabetes Branch of Chinese Research Hospital Association. Intervention for adults with pre-diabetes: a Chinese expert consensus. Chin J Endocrinol Metab. (2020) 36:371–80. doi: 10.3760/ cma.j.cn.1311282-20200115-00022

32. The Diabetes Prevention Program Research Group. The diabetes prevention program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care. (1999) 22:623–34. doi: 10.2337/diacare.22.4.623

33. Jensen MD, Ryan DH, Aupan CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation. (2014) 129(Suppl 2):S162–38. doi: 10.1161/01.cir.0000437379.71477.ee

34. Kolotkin R, Crosby R, Kosloski K, Williams G. Development of a brief measure to assess quality of life in obesity. Obes Res. (2001) 9:102–11. doi: 10.1038/oby.2001.13

35. Warkentin LM, Majumdar SR, Johnson JA, Agborsangaya CB, Rueda-Clausen CF, Sharma AM, et al. Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: two-year prospective cohort study. BMJ Med. (2014) 12:175. doi: 10.1136/bmjmed-2014-01075-5

36. Kolotkin R, Crosby R, Kosloski K, Williams G. Development of a brief measure to assess quality of life in obesity. Obes Res. (2001) 9:102–11. doi: 10.1038/oby.2001.13
51. Sun Y, Liu Y, Liu B, Zhou K, Yue Z, Zhang W, et al. Efficacy of acupuncture for chronic prostatitis/chronic pelvic pain syndrome: a randomized trial. *Ann Intern Med.* (2021) 174:1357–66. doi: 10.7326/m21-1814
52. Sun Y, Liu Y, Chen H, Yan Y, Liu Z. Electroacupuncture for stress-predominant mixed urinary incontinence: a protocol for a three-armed randomised controlled trial. *BMJ Open.* (2021) 11:e038452. doi: 10.1136/bmjopen-2020-038452
53. Bang H, Ni L, Davis CE. Assessment of blinding in clinical trials. *Control Clin Trials.* (2004) 25:143–56. doi: 10.1016/j.cct.2003.10.016
54. Li Y. Study on the Influencing Factors of Dietary Treatment Compliance in Patients with Type 2 Diabetes Mellitus by Using the Theory of Planned Behavior. Hebei: Hebei University (2017).
55. Ren HY, Tang P, Zhao QH. Development and evaluation of coronary artery disease self-management scale. *J Third Mil Med Univ.* (2009) 11:4.
56. HIS. Learning From Adverse Events Through Reporting and Review: A National Framework for Scotland. (2019). Available online at: https://www.healthcareimprovementscotland.org/our_work/governance_ and_assurance/learning_from_adverse_events/national_framework.aspx (accessed June 21, 2022).
57. Liang F, Koya D. Acupuncture: is it effective for treatment of insulin resistance? *Diabetes Obes Metab.* (2010) 12:555–69. doi: 10.1111/j.1463-1326.2009.01192.x
58. Huang XY, Zhang L, Sun J, Xu NG, Yi W. Acupuncture alters expression of insulin signaling related molecules and improves insulin resistance in OLETF rats. *Evid Based Complement Alternat Med.* (2016) 2016:9651592. doi: 10.1155/2016/9651592
59. Shu Q, Chen L, Wu S, Li J, Liu J, Xiao L, et al. Acupuncture targeting SIRT1 in the hypothalamic arcuate nucleus can improve obesity in high-fat-diet-induced rats with insulin resistance via an anorectic effect. *Obes Facts.* (2020) 13:40–57. doi: 10.1159/000503752
60. Yu Z, Xia Y, Ju C, Shao Q, Mao Z, Gu Y, et al. Electroacupuncture regulates glucose-inhibited neurons in treatment of simple obesity. *Neural Regen Res.* (2013) 8:809–16. doi: 10.3969/j.issn.1673-5374.2013.09.005

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yan, Sun, Wang, Zhu, Chen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.